Literature DB >> 23843306

Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome.

Cherie N Billingsley1, Jared R Allen, Douglas D Baumann, Samantha L Deitz, Joshua D Blazek, Abby Newbauer, Andrew Darrah, Brad C Long, Brandon Young, Mark Clement, R W Doerge, Randall J Roper.   

Abstract

Trisomy 21 in humans causes cognitive impairment, craniofacial dysmorphology, and heart defects collectively referred to as Down syndrome. Yet, the pathophysiology of these phenotypes is not well understood. Craniofacial alterations may lead to complications in breathing, eating, and communication. Ts65Dn mice exhibit craniofacial alterations that model Down syndrome including a small mandible. We show that Ts65Dn embryos at 13.5 days gestation (E13.5) have a smaller mandibular precursor but a normal sized tongue as compared to euploid embryos, suggesting a relative instead of actual macroglossia originates during development. Neurological tissues were also altered in E13.5 trisomic embryos. Our array analysis found 155 differentially expressed non-trisomic genes in the trisomic E13.5 mandible, including 20 genes containing a homeobox DNA binding domain. Additionally, Sox9, important in skeletal formation and cell proliferation, was upregulated in Ts65Dn mandible precursors. Our results suggest trisomy causes altered expression of non-trisomic genes in development leading to structural changes associated with DS. Identification of genetic pathways disrupted by trisomy is an important step in proposing rational therapies at relevant time points to ameliorate craniofacial abnormalities in DS and other congenital disorders.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  developmental delay disorders; experimental animal models; genotype-phenotype correlation; trisomy 21

Mesh:

Substances:

Year:  2013        PMID: 23843306      PMCID: PMC3729611          DOI: 10.1002/ajmg.a.36006

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  50 in total

Review 1.  Cranial neural crest and development of the head skeleton.

Authors:  Robert D Knight; Thomas F Schilling
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

2.  Genome-wide expression analysis of cultured trophoblast with trisomy 21 karyotype.

Authors:  U Rozovski; A Jonish-Grossman; A Bar-Shira; Y Ochshorn; M Goldstein; Y Yaron
Journal:  Hum Reprod       Date:  2007-07-17       Impact factor: 6.918

3.  Multiplex ligation-dependent probe amplification (MLPA) genotyping assay for mouse models of down syndrome.

Authors:  Chelsee Ann Hewitt; Catherine Louise Carmichael; Ella Jane Wilkins; Ping Zhi Fang Cannon; Melanie April Pritchard; Hamish Steele Scott
Journal:  Front Biosci       Date:  2007-05-01

4.  Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome.

Authors:  Lina Chakrabarti; Zygmunt Galdzicki; Tarik F Haydar
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

5.  Identification of dysregulated genes in lymphocytes from children with Down syndrome.

Authors:  Cesar A Sommer; Erika C Pavarino-Bertelli; Eny M Goloni-Bertollo; Flavio Henrique-Silva
Journal:  Genome       Date:  2008-01       Impact factor: 2.166

6.  Characterization of the cardiac phenotype in neonatal Ts65Dn mice.

Authors:  Austin D Williams; Corey H Mjaatvedt; Clara S Moore
Journal:  Dev Dyn       Date:  2008-02       Impact factor: 3.780

7.  HOXA5 acts directly downstream of retinoic acid receptor beta and contributes to retinoic acid-induced apoptosis and growth inhibition.

Authors:  Hexin Chen; Huiping Zhang; Jishin Lee; Xiaohui Liang; Xinyan Wu; Tao Zhu; Pang-Kuo Lo; Xiaokun Zhang; Saraswati Sukumar
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

8.  Relative rather than absolute macroglossia in patients with Down syndrome: implications for treatment of obstructive sleep apnea.

Authors:  Carolina V A Guimaraes; Lane F Donnelly; Sally R Shott; Raouf S Amin; Maninder Kalra
Journal:  Pediatr Radiol       Date:  2008-08-07

9.  Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes.

Authors:  E Aït Yahya-Graison; J Aubert; L Dauphinot; I Rivals; M Prieur; G Golfier; J Rossier; L Personnaz; N Creau; H Bléhaut; S Robin; J M Delabar; M-C Potier
Journal:  Am J Hum Genet       Date:  2007-07-19       Impact factor: 11.025

10.  Effects of aneuploidy on skull growth in a mouse model of Down syndrome.

Authors:  Cheryl A Hill; Roger H Reeves; Joan T Richtsmeier
Journal:  J Anat       Date:  2007-04       Impact factor: 2.610

View more
  4 in total

Review 1.  Stem and progenitor cell dysfunction in human trisomies.

Authors:  Binbin Liu; Sarah Filippi; Anindita Roy; Irene Roberts
Journal:  EMBO Rep       Date:  2014-12-17       Impact factor: 8.807

2.  Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.

Authors:  Samantha D McElyea; John M Starbuck; Danika M Tumbleson-Brink; Emily Harrington; Joshua D Blazek; Ahmed Ghoneima; Katherine Kula; Randall J Roper
Journal:  Hum Mol Genet       Date:  2016-11-15       Impact factor: 6.150

3.  DNA-Methylation Patterns in Trisomy 21 Using Cells from Monozygotic Twins.

Authors:  M Reza Sailani; Federico A Santoni; Audrey Letourneau; Christelle Borel; Periklis Makrythanasis; Youssef Hibaoui; Konstantin Popadin; Ximena Bonilla; Michel Guipponi; Corinne Gehrig; Anne Vannier; Frederique Carre-Pigeon; Anis Feki; Dean Nizetic; Stylianos E Antonarakis
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

4.  Green Tea Catechins Modulate Skeletal Development with Effects Dependent on Dose, Time, and Structure in a down Syndrome Mouse Model.

Authors:  Sergi Llambrich; Rubèn González-Colom; Jens Wouters; Jorge Roldán; Sara Salassa; Kaat Wouters; Vicky Van Bulck; James Sharpe; Zsuzsanna Callaerts-Vegh; Greetje Vande Velde; Neus Martínez-Abadías
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.